Atopic dermatitis treatment: Current state of the art and emerging therapies
Background:
Atopic dermatitis (AD) can be debilitating and often requires the use of combination topical and systemic therapy to achieve adequate disease control.
Methods:
A non-systematic review was performed of current state of the art and emerging therapies for AD.
Results:
There are a number of topical agents approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD and multiple nonapproved systemic agents that are used off label for the treatment of AD. All of these have limitations of efficacy and/or safety, which leads to a number of unmet disease-treatment needs. Recent insight has identified a number of novel pathways as treatment targets for AD, including the T-helper type 2 cytokines, interleukins (IL) 4, IL-13, IL-33, phosphodiesterase E 4, and Janus kinase signaling. Dupilumab is a monoclonal antibody that inhibits interleukin 4 and 13 signaling and was recently approved by the FDA for the treatment of moderate-severe AD in adults.
Discussion:
There are a number of current treatment approaches and emerging therapies for AD.
Atopic dermatitis (AD) can be debilitating and often requires the use of combination topical and systemic therapy to achieve adequate disease control.
Methods:
A non-systematic review was performed of current state of the art and emerging therapies for AD.
Results:
There are a number of topical agents approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD and multiple nonapproved systemic agents that are used off label for the treatment of AD. All of these have limitations of efficacy and/or safety, which leads to a number of unmet disease-treatment needs. Recent insight has identified a number of novel pathways as treatment targets for AD, including the T-helper type 2 cytokines, interleukins (IL) 4, IL-13, IL-33, phosphodiesterase E 4, and Janus kinase signaling. Dupilumab is a monoclonal antibody that inhibits interleukin 4 and 13 signaling and was recently approved by the FDA for the treatment of moderate-severe AD in adults.
Discussion:
There are a number of current treatment approaches and emerging therapies for AD.
Keywords: Atopic dermatitis; Janus Kinase (JAK); azathioprine; crisaborole; cyclosporine; dupilumab; glucocorticoids; immunosuppressants; interleukin 13 (IL-13); interleukin 4 (IL-4); lebrikizumab; methotrexate; nemolizumab; phosphodiesterase E 4 (PDE-4); tofacitinib; topical calcineurin inhibitors; topical corticosteroids; tralokinumab; treatment
Document Type: Research Article
Affiliations: Department of Dermatology, Preventive Medicine, and Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Publication date: 01 July 2017
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service. - Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Commercial level: Permission to use content
- www.JFoodAllergy.com
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content